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Abstract
Background: Rituximab (RTX) may favorably affect skin and lung fibrosis in patients with systemic sclerosis (SSc);
however, the underlying molecular mechanisms remain unknown. We aimed to explore the hypothesis that RTX
may mediate its antifibrotic effects by regulating the expression of Dickkopf-1 (Dkk-1), an inhibitor of the Wnt pathway.
Methods: Fourteen patients with SSc and five healthy subjects were recruited. Dkk-1 expression was
immunohistochemically assessed in skin biopsies obtained from 11 patients with SSc (8 treated with RTX and 3
with standard treatment), whereas DKK1 gene expression was assessed in 3 patients prior to and following RTX
administration.
Results: In baseline biopsies obtained from all patients with SSc but not in healthy subjects, Dkk-1 was undetectable
in skin fibroblasts. Following RTX treatment, four out of eight patients had obvious upregulation of Dkk-1 skin
expression. Similarly, RTX treatment correlated with a significant 4.8-fold upregulation of DKK1 gene expression
(p = 0.030). In contrast, TGFβ expression in the upper dermis was significantly attenuated following treatment.
Moreover, this decreased expression of TGFβ in the skin was significantly more pronounced in the subgroup of
patients with Dkk-1 upregulation. In this subgroup TGFβ was downregulated by 50.88 % in contrast to only 15.
98 % in patients who did not have Dkk-1 upregulation (p = 0.022).
Conclusions: This is the first study demonstrating a link between B cell depletion and skin Dkk-1 upregulation
in patients with SSc. RTX-mediated B cell depletion may mechanistically function via the recently established
TGFβ-Dkk-1 axis in improving skin fibrosis.
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Background
Systemic sclerosis (SSc) is a complex systemic rheumatic
disease characterized by autoimmunity, vasculopathy, and
aberrant fibroblast activation, eventually leading to fibro-
sis, tissue damage, and organ failure [1]. The therapeutic
armamentarium for SSc is very restricted; numerous ther-
apies have been tested and either failed or had a modest
effect. However, an increasing amount of clinical evidence
accumulated over the last few years suggests that B cell
depletion therapy may favorably affect skin and lung fibro-
sis in patients with SSc [2]. We have previously reported
that RTX treatment improves skin thickening and lung
function in patients with SSc [3]; this effect seems to be
further enhanced following long-term treatment [4, 5].
Similar data have been also reported by other research
groups [6–8]. Most importantly, recent large-scale multi-
center studies, including one from the European League
against Rheumatism Scleroderma Trial and Research
group, reported encouraging results, thus, supporting the
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concept of B cell depletion therapy in SSc [9, 10]. It is cur-
rently not known how RTX may mediate its potential
beneficial effects in SSc. However, experimental evidence
indicates that B cells are critically involved in the fibrotic
process [11–14].
SSc is a disease characterized by enhanced fibroblast
activation leading to increased collagen production and
eventually tissue fibrosis. There have been many theories
related to the drivers of aberrant fibroblast activation in
SSc; recent studies have provided strong experimental
data pointing to the direction of the canonical Wnt
pathway as a central mediator of the fibrotic process in
SSc [15–18]. The Wnt pathway is a developmental path-
way with β-catenin serving as the main signaling mol-
ecule. The activation of the Wnt pathway is strictly
controlled by several soluble inhibitors such as Dickkopf-1
(Dkk-1) [19]. Experimental data indicate that the Wnt
pathway is highly activated in the skin in scleroderma.
Dkk-1 is virtually undetectable in the skin of patients with
SSc in sharp contrast to healthy skin where it is clearly
expressed. Moreover, it was found that transforming
growth factor β (TGFβ), the most potent profibrotic mol-
ecule that is crucially involved in the pathophysiology of
SSc, downregulates Dkk-1 expression [20]. These data
have unraveled a previously unknown link between TGFβ
and the Wnt pathway (TGFβ→ downregulation of
Dkk-1→ upregulation of the Wnt pathway→ fibrosis)
and have highlighted the role of Dkk-1 in the fibrotic
process.
In our study we aimed to explore the hypothesis that
B cell depletion therapy may mediate its antifibrotic ef-
fects via the Wnt pathway. More specifically, we aimed
to assess (1) expression of Dkk-1 and TGFβ in the skin
and circulating levels in patients with SSc prior to and
following B cell depletion therapy and (2) DKK1 gene
expression in cultured fibroblasts obtained from patients
with SSc prior to and following B cell depletion therapy.
We report herein that Dkk-1 is upregulated following
B cell depletion therapy in a subset of patients with SSc;
these patients exhibit the most profound reduction in
skin fibrosis following treatment.
Methods
Patients
Fourteen patients with SSc, fulfilling the preliminary
American College of Rheumatology criteria for the clas-
sification of the disease [21], were recruited. Eleven pa-
tients were originally enrolled in a proof of concept
study performed in our institution, assessing the clinical
efficacy of RTX in SSc [3]. In this study, eight patients
were randomized to the treatment arm and received two
courses of RTX (at baseline and at 6 months), and six
patients were randomized to the control arm and received
standard therapy. Skin biopsies from clinically involved
skin were obtained from all patients in the treatment
group (n = 8) and in three patients in the control group (at
baseline and at 6 months). Skin biopsies from these 11 pa-
tients were immunohistochemically assessed. Three add-
itional patients with SSc treated with RTX, were similarly
subjected to skin biopsies at baseline and at 6 months;
these biopsies were used for fibroblast extraction and gene
expression analysis.
Demographic and clinical characteristics of the study
subjects and clinical outcomes following treatment have
already been reported in detail elsewhere [3]. Briefly, all
patients had diffuse disease, were anti-Scl70 positive, and
had no change in medication and/or dosage of treatment
administered during the last 12 months before enrollment.
Patients in the RTX group had a significant improvement
in pulmonary function tests (PFTs) and skin thickening
at 1 year (following two courses of RTX treatment)
compared to baseline. There was a significant increase in
forced vital capacity (FVC) (mean ± SD 68.13 ± 19.69 vs
75.63 ± 19.73, at baseline vs 1 year, respectively, p = 0.0018)
and diffusing lung capacity for carbon monoxide (DLco)
(mean ± SD 52.25 ± 20.71 vs. 62 ± 23.21, at baseline vs
1 year, respectively, p = 0.017) in the RTX group. The
modified Rodnan skin score (MRSS) also improved sig-
nificantly in the RTX group compared to the baseline
score (mean ± SD, 13.5 ± 6.84 vs 8.37 ± 6.45, at baseline
vs 1 year, respectively, p < 0.001).
As a disease control group for the current study we
used three patients from the control arm of the original
study, for whom skin biopsies were available. Two of
these patients were receiving cyclophosphamide, whereas
the third patient received no treatment. Skin biopsies from
five age-matched and sex-matched healthy subjects were
evaluated as healthy controls.
The study has been approved by a local Ethics Commit-
tee (Patras University Hospital, Patras, Greece) and written
informed consent was obtained from all participating
individuals.
Assessment of circulating levels of Dkk-1, TGFβ and IL-6
Circulating Dkk-1, TGFβ and IL-6 levels were measured
using a solid phase immunoassay, according to the
manufacturer’s instructions (R&D Systems, MN, USA).
All measurements were performed in triplicates for each
sample and the mean value was calculated.
Skin histology and immunohistochemistry
Skin biopsies of 5 mm were taken from skin affected by
lesions on the forearm. All biopsies were fixed in 10 %
neutral buffered formalin and embedded in paraffin. Dkk-1
and TGFβ expression were immunohistochemically
assessed using mouse anti-human monoclonal antibodies
(R&D Systems, MN, USA); analysis was performed separ-
ately for the upper and lower dermis. Masson’s trichrome
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was used for skin collagen visualization and fibrosis
evaluation. Computerized image analysis using the Image
J software was used to quantify the results as previously
described [3, 22].
Extraction and culture of skin fibroblasts
Biopsies were mechanically minced using a scalpel and then
fibroblasts were extracted using a standard protocol. Fibro-
blasts were cultured in EMEM supplemented with 10 %
FBS and antibiotics (penicillin (100 U/ml), streptomycin
(100 mg/ml)); fibroblasts from the third to the fifth passages
were used for experiments. In some experiments fibroblasts
(obtained from healthy subjects and patients with SSc) were
treated with serum obtained from patients with SSc (n = 3)
prior to and 6 months after treatment with RTX or serum
obtained from healthy controls. These experiments were
performed to explore whether soluble factors affect DKK1
expression in skin fibroblasts. In these experiments fibro-
blasts were subjected to 24 hours starvation prior to treat-
ment with 10 % human serum for another 24 hours.
Fibroblast lysis, RNA extraction and DKK1 gene expression
Cells were detached using trypsin, lysed, and subjected to
mRNA extraction according to a standard protocol (RNeasy
Mini Kit, Qiagen) following manufacturer’s instructions.
RNA purity was confirmed using a NanoDrop Spectropho-
tometer (Thermo Scientific). cDNA synthesis was carried
out using the iScript cDNA synthesis kit (Bio-Rad
Laboratories, Hercules, CA, USA) from 1 μg of total RNA.
DKK1, Thrombospondin 1 (THBS1) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mRNA relative
expression levels were assessed, using the iTaq Universal
SYBR Green supermix (Bio-Rad Laboratories) with CFX96
Touch Real-time System (Bio-Rad Laboratories). For human
DKK1, THBS1 and GAPDH gene-specific KiCqStart™
primers were purchased from Sigma-Aldrich Co. The rela-
tive expression level of the gene of interest was calculated
with the comparative 2ΔΔCΤ method and all samples were
normalized to GAPDH. All experiments were independently
performed in duplicate three times, each time using 1 μg of
template RNA.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
software version 5. Data are presented as mean± SEM, me-
dian (lower and upper quartile values), or percentages, as ap-
propriate. Student’s t test was used for comparisons between
groups. Significance was defined as p < 0.05 (two-tailed).
Results
Dkk-1 deficiency in the skin of patients with scleroderma
is restored following B cell depletion therapy
Dkk-1 was expressed in the epidermis, appendices, and
fibroblasts in the dermis in all the biopsies obtained
from healthy subjects. In sharp contrast, in all baseline
biopsies obtained from patients with SSc (n = 11), Dkk-1
was virtually undetectable in skin fibroblasts. In fact,
weak Dkk-1 staining was detected at the epidermis in
only two patients (one from the RTX and one from the
disease control group). Representative histological analysis
of normal skin and the human colon (used as a positive
control for Dkk-1 expression) is shown in Fig. 1. These
data confirm previously reported results [20].
Following B cell depletion therapy, four out of eight
patients had obvious expression of Dkk-1 in skin fibro-
blasts, in sharp contrast to the disease control group in
whom there was no Dkk-1 expression seen in fibroblasts
in the follow-up biopsies. Representative histological ana-
lysis from a patient showing Dkk-1 upregulation after
RTX treatment is shown in Fig. 2. Histological analysis of
biopsies from all remaining patients is shown in the
Additional files (see Additional file 1: Figures S1-S3 for
depiction of patients with Dkk-1 upregulation after
RTX treatment, Additional file 2: Figures S4-S6 and
Additional file 3: Figure S7 for depiction of patients
with no Dkk-1 upregulation after RTX treatment, and
Additional file 4: Figures S8-S10 for depiction of patients
in the disease control group).
B cell depletion therapy significantly induces DKK1 gene
expression in skin
We first evaluated the expression of the DKK1 gene in
scleroderma compared to normal fibroblasts. There was
significant 4.1-fold downregulation of DKK1 expression
in fibroblasts from patients with scleroderma compared
to normal fibroblasts (p < 0.001) as shown in Fig. 3a. We
next assessed whether B cell depletion therapy affects
the expression of the DKK1 gene in the skin. To address
this question we analyzed DKK1 gene expression in fibro-
blasts extracted from skin biopsies from three patients
with SSc treated with RTX (at baseline and 6 months after
treatment). All three patients responded clinically with a
significant decline of >30 % in the MRSS. There was
significant 4.2-fold upregulation of DKK1 expression
following RTX treatment (p = 0.030) as shown in Fig. 3b.
Levels of Dkk-1 and TGFβ expression in skin from patients
with SSc are inversely correlated
Taking into account recently reported data indicating that
TGFβ regulates Dkk-1 expression, we next asked whether
TGFβ skin expression is modified following B cell deple-
tion therapy. In skin, TGFβ expression (assessed immuno-
histochemically) in fibroblasts from the upper dermis was
significantly attenuated following RTX treatment (mean ±
SEM 32.72 ± 4.67 vs 20.21 ± 3.08, at baseline and at
6 months, respectively, p = 0.01). However, the down-
regulation of TGFβ expression in skin was significantly
more pronounced in the subgroup of patients (n = 4)
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with upregulation of Dkk-1. More specifically, in this
subgroup TGFβ was downregulated by a mean percent-
age (± SEM) of 50.88 % (±10.81) in sharp contrast to
only 15.98 % (±3.73) in patients with no upregulation
of Dkk-1 (p = 0.02) (Fig. 4e). Representative histological
analysis from a patient with significant downregulation
of TGFβ expression in skin is also shown in Fig. 4a-d.
In the disease control group there was no change in TGFβ
expression in the upper dermis (mean ± SEM 27.37 ± 6.76
vs 29.0 ± 2.15, at baseline and at 6 months, respectively, p
value not significant). There were no changes in TGFβ ex-
pression in the lower dermis in either patient group. We
Fig. 1 Dickkopf-1 (Dkk-1) is expressed in the normal colon and skin. Dkk-1 expression in a section from a positive control (normal colon) (a, b). Note the
cytoplasmic expression in the basis of crypt epithelium (black arrows). Streptavidin biotin peroxidase: magnification × 20 (a), × 400 (b). Dkk1-expression in
a section from normal skin (c, d). Dkk-1 is clearly expressed at the epidermis (black arrows), appendices (green arrows) and spindle-like cells (red arrow).
Streptavidin biotin peroxidase: magnification × 20 (c), × 400 (d)
Fig. 2 Dickkopf-1 (Dkk-1) is upregulated responders to rituximab (RTX) therapy. In the baseline biopsy (a, b) Dkk-1 is not expressed in the epidermis
(black arrow), appendices (green arrow), and spindle-like cells (red arrows). Following RTX treatment (d, e) there is clear expression of Dkk-1 in
the epidermis (black arrow), appendices (green arrow) and spindle-like cells (red arrows). Streptavidin biotin peroxidase: magnification × 20 (a, d), × 400
(b, e). Upregulation of Dkk-1 expression is associated with a decrease in collagen accumulation (prior to (c) and after (f) RTX treatment).
Masson’s trichrome × 100
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further analyzed the expression of THBS1, a well-known
target of TGFβ, in skin fibroblasts obtained from two pa-
tients with SSc prior to and 6 months after treatment with
RTX. THBS1 expression was downregulated (by 37.93 %
and 50.90 %, respectively) in both patients. Collectively
these data indicate that B cell depletion therapy is associ-
ated with downregulation of TGFβ expression in skin; this
downregulation is more pronounced in the subset of SSc
patients with upregulation of Dkk-1.
Upregulation of Dkk-1 in skin is associated with enhanced
resolution of skin fibrosis
We further explored potential differences in histologic
response between patients who had and those who did
not have upregulation of Dkk-1. Patients with upregula-
tion of Dkk-1 skin expression (n = 4) had an enhanced
histologic response in the resolution of skin fibrosis. More
specifically, on histologic analysis of skin from these pa-
tients, Dkk-1 upregulation was associated with a signifi-
cant decrease in collagen accumulation in the upper
dermis by a mean ± SEM 49.47 ± 10.63 %, compared to
18.18 ± 6.67 % in patients who did not have upregulation
of Dkk-1 (p = 0.04) (Fig. 5). Histologic data matched the
clinical data; the MRSS at 1 year (following two cycles of
RTX treatment at baseline and at 6 months) decreased
by a median of 63.33 % (24.34–72.92) in the subgroup
with Dkk-1 upregulation compared to only 28.08 %
(27.35–44.64) in the subgroup with undetectable Dkk-1;
Fig. 3 Dickkopf-1 (DKK1) gene is downregulated in scleoderma fibroblasts. Rituximab (RTX) treatment upregulates DKK1 gene expression in the skin.
Fibroblasts from patients with systemic sclerosis had 4.1-fold downregulation of DKK1 gene expression compared to normal fibroblasts (p < 0.001) (a).
RTX treatment mediates significant 4.2-fold upregulation of skin DKK1 gene expression (p = 0.030) (b)
Fig. 4 Rituximab (RTX) treatment correlates with significant attenuation of transforming growth factor β (TGFβ) expression in the skin. TGFβ is
strongly expressed in the vast majority of spindle-like cells at baseline (red arrows) (a, b). Following RTX treatment significant attenuation of TGFβ
expression is seen; many spindle-like cells do not express TGFβ (blue arrows) (c, d). Streptavidin biotin peroxidase: magnification × 20 (a, c), × 400
(b, d). Downregulation of TGFβ expression is more pronounced in the subgroup of patients with upregulation of Dkk-1 following RTX treatment
(Dkk+) compared to the subgroup of patients who did not have upregulation of Dkk-1 following RTX treatment (Dkk-) (e)
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however this was not statistically significant. PFTs im-
proved following RTX treatment, irrespective of Dkk-1
expression in skin.
B cell depletion in skin is associated with Dkk-1 upregula-
tion following RTX treatment
We next explored potential mechanisms of DKK1 up-
regulation in the skin following RTX treatment. We first
aimed to explore whether circulating factors participate;
to do so we assessed circulating levels of Dkk-1, TGFβ
and IL-6 prior to and following B cell depletion therapy.
Circulating levels of Dkk-1 did not change following treat-
ment (mean ± SEM optical density (OD) 0.17 ± 0.04 vs
0.19 ± 0.03, prior to and following treatment, respectively,
p value not significant). Serum TGFβ levels remained un-
changed (mean ± SEM OD: 2.01 ± 0.38 vs 2.41 ± 0.36,
prior to and following treatment respectively, p value not
significant). This was also true for IL-6 levels (mean ±
SEM OD 0.35 ± 0.07 vs 0.37 ± 0.11, prior to and following
treatment, respectively, p value not significant). To assess
whether other circulating factors may mediate DKK1 up-
regulation we treated normal fibroblasts and fibroblasts
from patients with scleroderma with serum obtained from
patients with SSc (n = 3) prior to and 6 months after RTX
treatment. DKK1 gene expression in fibroblasts treated
with serum obtained from patients with SSc prior to
RTX treatment was similar to DKK1 gene expression in
fibroblasts treated with serum obtained from SSc pa-
tients after RTX treatment, as shown in Fig. 6a (normal fi-
broblasts) and 6b (fibroblasts from patients with SSc).
We further assessed whether skin B cell depletion may
correlate with DKK1 upregulation. Skin-infiltrating B cells
were present in all patients with SSc in relatively small
numbers; details have been previously reported [3, 5].
Briefly, RTX treatment effectively depleted skin-infiltrating
B cells in four out of eight patients assessed. In the sub-
group of patients who had Dkk-1 upregulation following
RTX treatment (n = 4); three patients also had effective B
cell depletion in the skin. In sharp contrast, in the sub-
group of patients who did not have upregulation of Dkk-1
(n = 4), effective B cell depletion in the skin was evident in
one patient only. These data suggest a potential link be-
tween skin B cell depletion and Dkk-1 upregulation.
Discussion
Even though clinical data pointing to the direction of a
beneficial role of RTX in SSc continue to emerge, the
critical question of how B cell depletion therapy may
mediate its antifibrotic effects remains largely unanswered.
In animal models of SSc, B cells exhibit a disturbed
Fig. 5 Upregulation of Dickkopf-1 (Dkk-1) in skin is associated with
enhanced resolution of skin fibrosis. Dkk-1 upregulation following ri-
tuximab treatment is associated with a significant decrease in colla-
gen accumulation in the upper dermis compared to patients who
did not have upregulation of Dkk-1 (p = 0.040)
Fig. 6 Circulating factors do not participate in Dickkopf-1 (DKK1) gene upregulation following rituximab (RTX) treatment. DKK1 gene expression in
fibroblasts treated with serum obtained from patients with systemic sclerosis (SSc) prior to RTX treatment was similar to DKK1 gene expression in
fibroblasts treated with serum obtained from patients with SSc following RTX treatment: a normal fibroblasts; b fibroblasts from patients with SSc
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phenotype by displaying increased CD19 signaling and
hyper-responsiveness [23]. There is strong evidence that
RTX effectively ameliorates collagen accumulation in
these models [13], indicating a link between B cells and
the fibrotic process.
Evidence from patients with SSc indicate that B cells
are present locally in fibrotic tissue in both skin [24] and
lung [25]; most importantly, gene expression analysis
has revealed a B cell signature in the skin in scleroderma
[26]. Even though these data suggests that B cells are
active players in fibrosis, the exact mechanisms in-
volved are not entirely known. In order to reveal these
mechanisms one must explore how B cells may directly
or indirectly interact with fibroblasts, the cell type re-
sponsible for collagen overproduction.
There are three potential ways whereby B cells may
interact with fibroblasts [27]. First, B cells may produce
agonistic fibroblast-stimulating auto-antibodies (Abs), such
as anti-platelet-derived growth factor receptor (PDGFR)
Abs [28]. A second way is by producing soluble mediators;
B cells can produce TGFβ and IL-6, which are cytokines
strongly involved in the pathophysiology of fibrosis. Finally,
recent evidence suggests that B cells can stimulate fi-
broblasts in vitro via a contact-dependent mechanism.
Francois et al. have shown that when scleroderma fibro-
blasts are co-cultured with B cells, there is significant
upregulation of collagen production [29]. Interestingly,
the effect of B cells on collagen production in this ex-
perimental model was comparable to that of TGFβ, one
of the most important profibrotic molecules known.
Moreover, it was shown that the effect of B cells on fibro-
blasts in this experimental model is contact-dependent
and at least partially mediated by TGFβ.
In this study we provide experimental evidence, at
both protein and gene expression level, that RTX treat-
ment may affect Dkk-1 skin expression in patients with
SSc. This is the first study to suggest a link between B
cell depletion and Dkk-1 expression in skin. Dkk-1 is
strikingly absent from the skin in scleroderma; however,
in a subset of patients with SSc, this molecule is upregu-
lated following RTX treatment. More importantly, the
patients with Dkk-1 upregulation have the more profound
histologic response to B cell depletion therapy. Our data
indicate that the upregulation of Dkk-1 may represent a
specific effect of RTX treatment, as it was not observed in
patients with SSc who were receiving standard treatment
including cyclophosphamide; however, our results should
be interpreted with caution, taking into account the
limited number of patients assessed. These data reinforce
existing evidence that Dkk-1 is a crucial mediator of
the fibrotic process.
A critical question is how RTX may affect the expression
of Dkk-1 in skin. It is currently unknown whether RTX
mediates its potential antifibrotic effects by depleting B
cells or by other mechanisms; it is known that RTX has a
broad effect on the immune system [30]. In this study we
found a strong association between skin B cell depletion
and Dkk-1 upregulation/histologic response. This strong
association suggests that B cells in skin, or other, so far
unknown factor(s), may potentially suppress Dkk-1 ex-
pression in fibroblasts and therefore, effective B cell de-
pletion in skin alleviates this suppression, leading to
Dkk-1 upregulation. If indeed this is true and B cells
are responsible for the striking lack of Dkk-1 expression
in fibroblasts from patients with scleroderma, the next
question is how B cells mediate this effect. Our data
suggest that this may be a TGFβ-dependent effect. It is
also of interest that circulating levels of Dkk-1 and
TGFβ did not change following treatment, indicating
that the whole process is taking place in the affected
tissues such as the skin; this is in accordance with pre-
viously reported data [31].
Our study has several potential limitations. The first
one is the relatively small number of patients assessed,
therefore, definite conclusions cannot be drawn. The
second limitation is that the expression of TGFβ in skin
was assessed mainly by immunohistochemical analysis,
which cannot distinguish between active and latent
forms of TGFβ. Therefore, the evidence provided in our
study implicating TGFβ in the regulation of Dkk-1 ex-
pression should not be considered powerful. Further
studies are needed to clarify the potential role of TGFβ
in this process. Moreover, an additional limitation is that
Wnt pathway activation in the skin was not assessed.
Conclusions
This is the first study that demonstrates a link between
B cell depletion and upregulation of Dkk-1 in the skin of
patients with SSc. Moreover, patients with upregulation of
Dkk-1 following RTX treatment have the best histologic
response to treatment. Large-scale randomized controlled
studies assessing the efficacy of RTX in SSc are highly
needed.
Additional files
Additional file 1: Figures S1-S3. In the baseline biopsy (A and B) Dkk-1
is not expressed in epidermis (black arrow), appendices (green arrow) and
spindle-like cells (red arrows). In the follow up biopsy (C and D) there is clear
expression of Dkk-1 in epidermis (black arrow), appendices (green arrow)
and spindle-like cells (red arrows). All three patients responded to RTX
treatment. Streptavidin biotin peroxidase (A and D × 20, B and E × 400)
(ZIP 5323 kb)
Additional file 2: Figures S4-S6. Dkk-1 is not expressed in epidermis
(black arrow), appendices (green arrow) and spindle-like cells (red arrows)
prior to (A and B) and following RTX treatment (D and E). These patients
did not respond to RTX treatment. Streptavidin biotin peroxidase (A and
D × 20, B and E × 400) (ZIP 5591 kb)
Additional file 3: Figure S7. Dkk-1 is not expressed in epidermis (black
arrow), appendices (green arrow) and spindle-like cells (red arrows) in both
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baseline (A and B) and follow up biopsy (D and E) in a non responder.
Streptavidin biotin peroxidase (A and D × 20, B and E x400). RTX treatment
had no effect on collagen accumulation (C and F, prior to and following
RTX treatment, respectively). Masson’s trichrome × 100 (TIF 876 kb)
Additional file 4: Figures S8-S10. Dkk-1 is not expressed in epidermis
(black arrow), appendices (green arrow) and spindle-like cells (red arrows)
in the control patient group at baseline (A and B) and follow up biopsies
(D and E). Streptavidin biotin peroxidase (A and D × 20, B and E × 400)
(ZIP 5018 kb)
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Dkk-1: Dickkopf-1; DLCO: diffusing lung capacity for carbon monoxide;
FBS: fetal bovine serum; FVC: forced vital capacity; GAPDH: glyceraldehyde
3-phosphate dehydrogenase; IL-6: intrleukin-6; MRSS: modified Rodnan skin
score; OD: optical density; PDGFR: platelet-derived growth factor receptor;
PFT: pulmonary function test; RTX: rituximab; SEM: standard error of the
mean; SSc: systemic sclerosis; TFGβ: transforming growth factor β.
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